C3 and neoplasm: In a more recent study, Davidson and colleagues observed that the neutralization of C3a (using a blocking anti-C3a or a pharmacological antagonist of C3aR) leads to a reduction of the tumor mass and is associated with an increase in non-differentiated pro-inflammatory Ly6C+ subpopulations of monocytes [30].